Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19.

Expression of a BCR is critical for B-cell development and survival. We have identified 4 patients with agammaglobulinemia and markedly reduced but detectable B cells in the peripheral circulation. These B cells have an unusual phenotype characterized by increased expression of CD19 but no BCR. The cells are positive for CD20, CD22, and CD38, but not for Annexin 5 or activation markers, including CD69, CD83, or CD86. EBV lines derived from these B cells lack functionally rearranged immunoglobulin heavy-chain transcripts, as shown by PCR-rapid amplification of cDNA ends (PCR-RACE). Analysis of BM from 2 of the patients showed a severe reduction in the number of pro-B cells as well as pre-B cells. Functionally rearranged heavy-chain transcripts were identified, indicating that machinery to rearrange immunoglobulin genes was intact. Flow cytometry of B-lineage cells suggested accelerated acquisition of maturation markers in early B-cell precursors and increased phosphorylation of signal transduction molecules. Further, expression of TdT, a molecule that is normally down-regulated by a functional pre-BCR complex, was decreased. We hypothesize that the accelerated maturation, increased expression of CD19, and lack of a BCR were due to the constitutive activation of the BCR signal transduction pathway in these patients.

[1]  J. Dongen,et al.  B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele , 2010, Genes and Immunity.

[2]  R. Watanabe,et al.  Differential phosphorylation of functional tyrosines in CD19 modulates B‐lymphocyte activation , 2010, European journal of immunology.

[3]  M. van der Burg,et al.  CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. , 2010, The Journal of clinical investigation.

[4]  R. DePinho,et al.  PI3 Kinase Signals BCR-Dependent Mature B Cell Survival , 2009, Cell.

[5]  K. Schwarz,et al.  Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells , 2009, Proceedings of the National Academy of Sciences.

[6]  Sandra D'Alfonso,et al.  Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus , 2008, Nature Genetics.

[7]  H. Koeppen,et al.  High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate , 2007, British journal of haematology.

[8]  V. Tybulewicz,et al.  CD19 is essential for B cell activation by promoting B cell receptor–antigen microcluster formation in response to membrane-bound ligand , 2008, Nature Immunology.

[9]  V. Lougaris,et al.  Mutations of the Igβ gene cause agammaglobulinemia in man , 2007, The Journal of experimental medicine.

[10]  M. Conley,et al.  Cutting Edge: A Hypomorphic Mutation in Igβ (CD79b) in a Patient with Immunodeficiency and a Leaky Defect in B Cell Development1 , 2007, The Journal of Immunology.

[11]  S. Tangye,et al.  Expansion of Functionally Immature Transitional B Cells Is Associated with Human-Immunodeficient States Characterized by Impaired Humoral Immunity1 , 2006, The Journal of Immunology.

[12]  K. Tokunaga,et al.  FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling , 2005 .

[13]  P. Lipsky,et al.  Identification and characterization of circulating human transitional B cells. , 2005, Blood.

[14]  K. Tokunaga,et al.  FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. , 2005, Human molecular genetics.

[15]  M. Fujimoto,et al.  Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. , 2004, Arthritis and rheumatism.

[16]  I. Mårtensson,et al.  Surface μ Heavy Chain Signals Down-Regulation of the V(D)J-Recombinase Machinery in the Absence of Surrogate Light Chain Components , 2004, The Journal of experimental medicine.

[17]  M. Conley,et al.  Females with a disorder phenotypically identical to X-linked agammaglobulinemia , 1992, Journal of Clinical Immunology.

[18]  S. Desiderio,et al.  Mimicry of Pre–B Cell Receptor Signaling by Activation of the Tyrosine Kinase Blk , 2003, The Journal of experimental medicine.

[19]  S. Levy,et al.  The Tetraspanin CD81 Regulates the Expression of CD19 During B Cell Development in a Postendoplasmic Reticulum Compartment 1 , 2003, The Journal of Immunology.

[20]  Mary Ellen Conley,et al.  Clinical and molecular analysis of patients with defects in μ heavy chain gene , 2002 .

[21]  K. Tokunaga,et al.  Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese , 2002, Genes and Immunity.

[22]  R. Hendriks,et al.  Composition of Precursor B-Cell Compartment in Bone Marrow from Patients with X-Linked Agammaglobulinemia Compared with Healthy Children , 2002, Pediatric Research.

[23]  B. Stollar,et al.  Human immunoglobulin variable region gene analysis by single cell RT-PCR. , 2000, Journal of immunological methods.

[24]  R. Longnecker,et al.  Epstein-Barr Virus LMP2A-Induced B-Cell Survival in Two Unique Classes of EμLMP2A Transgenic Mice , 2000, Journal of Virology.

[25]  T. Tedder,et al.  CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification , 2000, Immunologic research.

[26]  R. Longnecker,et al.  Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. , 2000, Journal of virology.

[27]  D. Campana,et al.  An essential role for BLNK in human B cell development. , 1999, Science.

[28]  D. Campana,et al.  Mutations in Igα (CD79a) result in a complete block in B-cell development , 1999 .

[29]  F. Grosveld,et al.  Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. , 1999, Journal of immunology.

[30]  F. Alt,et al.  Activated Ras Signals Developmental Progression of Recombinase-activating Gene (RAG)-deficient Pro-B Lymphocytes , 1999, The Journal of experimental medicine.

[31]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[32]  H. Dintzis,et al.  Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Campana,et al.  Mutations in the Human λ5/14.1 Gene Result in B Cell Deficiency and Agammaglobulinemia , 1998, The Journal of experimental medicine.

[34]  R. Geha,et al.  Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Rajewsky,et al.  In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death , 1997, Cell.

[36]  S. Sato,et al.  CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. , 1997, Journal of immunology.

[37]  R. Hardy,et al.  Down-regulation of terminal deoxynucleotidyl transferase by Ig heavy chain in B lineage cells. , 1997, Journal of immunology.

[38]  D. Campana,et al.  Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. , 1996, The New England journal of medicine.

[39]  E. Kremmer,et al.  Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction , 1996, Journal of virology.

[40]  F. E. Bertrand,et al.  Immunoglobulin recombinase gene activity is modulated reciprocally by interleukin 7 and CD19 in B cell progenitors , 1995, The Journal of experimental medicine.

[41]  R. Brezinschek,et al.  Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. , 1995, Journal of immunology.

[42]  B. Koller,et al.  Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. , 1995, Immunity.

[43]  Andrew H. Liu,et al.  THE GENE INVOLVED IN X-LINKED AGAMMAGLOBULINEMIA IS A MEMBER OF THE SRC FAMILY OF PROTEIN-TYROSINE KINASES , 1994, Pediatrics.

[44]  Ornella Parolini,et al.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia , 1993, Cell.

[45]  D. Bentley,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.

[46]  S. Levy,et al.  The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. , 1992, Journal of immunology.

[47]  D. Fearon,et al.  CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. , 1992, Science.

[48]  C. Goodnow,et al.  Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens , 1991, Nature.

[49]  D. Campana,et al.  Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. , 1990, Journal of immunology.

[50]  K. Rajewsky,et al.  Membrane‐bound IgM obstructs B cell development in transgenic mice , 1989, European journal of immunology.

[51]  M R Loken,et al.  Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. , 1987, Blood.

[52]  M. Conley.  B cells in patients with X-linked agammaglobulinemia. , 1985, Journal of immunology.

[53]  M. Cooper,et al.  B lymphocyte precursors in human bone marrow: an analysis of normal individuals and patients with antibody-deficiency states. , 1978, Journal of immunology.